Teva Pharmaceutical Industries Ltd.
Profile managed by Bizz IdDescription
Products
24 productsBrand: Simlandi (adalimumab-ryvk in the US). Biosimilar to Humira. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Ahzantive. Biosimilar to Eylea. Partners: Klinge Biopharma and Formycon (EEA excl. Italy, UK, Switzerland, Israel).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Eylea. Ophthalmology. Under regulatory review. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Bevacizumab-Teva. Biosimilar to Avastin. Partner: mAbxience.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
US brand: Ponlimsi (denosumab-adet). Biosimilar to Prolia. Osteoporosis. Launched regionally in Europe.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
US brand: Degevma (denosumab-adet). Biosimilar to Xgeva. Oncology. Launched regionally in Europe.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Code TEV-'574. Ulcerative colitis and Crohn's disease. Phase 3. Partner: Sanofi.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Epysqli (eculizumab-aagh in the US). Biosimilar to Soliris. US partner: Samsung Bioepis.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brands: Tevagrastim (EU, Israel, Brazil, Russia, Chile, Turkey, Paraguay), Inmunef (Mexico), Filgrastim Teva (South Africa), Granix (tbo-filgrastim, US). Biosimilar to Neupogen (biosimilar only per EMA; Granix is not considered a biosimilar in the US).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Ajovy (fremanezumab-vfrm in the US). Teva originator biologic. Injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Simponi Aria. Immunology. Under regulatory review. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Simponi. Immunology. Under regulatory review. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Ocrevus. Neurology. Pre-clinical. Partner: Polpharma.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq). Neurology. Pre-clinical. Partner: Polpharma.
Under development
Finished product (FDF)
Verified on 2026-10-21
Ocrelizumab: see suppliers → · Hyaluronidase: see suppliers →
Biosimilar to Xolair. Immunology, respiratory. Under regulatory review.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brands: Ranivisio (EU), Ranopto (Canada), Ongavia (UK). Biosimilar to Lucentis. Partner: Bioeq.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Cinqair. Teva originator biologic. Injection.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Truxima (rituximab-abbs in the US). Biosimilar to Rituxan. US and Canada partner: Celltrion.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Anti-PD1-IL2 (Attenukine). Oncology. Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Anti-IL-15. Celiac disease: Phase 2. Vitiligo: Phase 1.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Herzuma (trastuzumab-pkrb in the US). Biosimilar to Herceptin. US and Canada partner: Celltrion.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Selarsdi (ustekinumab-aekn in the US). Biosimilar to Stelara. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Entyvio (IV). Immunology. Under regulatory review. US partner: Alvotech.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Entyvio SC. Immunology. Clinical stage. US partner: Alvotech.
Under development
Finished product (FDF)
Verified on 2026-10-21